Oxytocin API is a synthetic cyclic nonapeptide hormone and uterotonic active pharmaceutical ingredient used primarily in obstetric medicines. Oxytocin is structurally a cyclic nonapeptide containing a disulfide bridge between cysteine residues 1 and 6. Its amino-acid sequence is Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH₂ (CYIQNCPLG). PubChem identifies oxytocin with molecular formula C₄₃H₆₆N₁₂O₁₂S₂, CAS 50-56-6, and molecular weight 1007.2 g/mol.
Unlike conventional small-molecule APIs, oxytocin is a peptide API, so its quality assessment requires peptide-specific analytical and biological testing. The Indian Pharmacopoeia Commission's current draft proposal describes oxytocin as a synthetic cyclic nonapeptide and specifies a content range of 93.0% to 102.0%, calculated on the anhydrous and acetic-acid-free basis.
Oxytocin is a naturally occurring peptide hormone produced by the posterior pituitary and is responsible for stimulating uterine contractions and milk ejection. Pharmaceutical oxytocin is generally manufactured synthetically and is used in controlled medicinal formulations.
The API is particularly important in obstetric medicine because oxytocin stimulates uterine contraction. It is used in pharmaceutical products associated with induction or augmentation of labour and management of postpartum haemorrhage, according to the approved indication and dosage form.
Oxytocin is also used in formulations intended to support uterine contraction after childbirth. Because it is a peptide and highly potent biologically, pharmaceutical-quality manufacturing requires tight control of identity, peptide purity, biological activity and degradation products.
Oxytocin contains nine amino-acid residues and a characteristic intramolecular disulfide bond. The peptide sequence is:
Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH₂
The molecular formula is C₄₃H₆₆N₁₂O₁₂S₂, with molecular weight 1007.2 g/mol. PubChem identifies oxytocin as a heterodetic cyclic peptide and peptide hormone.
The disulfide bridge is essential to the characteristic cyclic structure and biological activity of oxytocin. Consequently, analytical characterization needs to demonstrate both peptide identity and appropriate structural integrity.
Oxytocin API is principally used for manufacturing parenteral pharmaceutical preparations. Its principal applications include:
Oxytocin is classified as a uterine stimulant/oxytocic agent. The Indian Pharmacopoeia Commission draft monograph specifically categorizes it under Uterine stimulant.
Oxytocin requires specialized quality-control procedures because peptide content and biological activity are not completely represented by a conventional small-molecule assay.
The Indian Pharmacopoeia draft proposal states that oxytocin contains 93.0–102.0% of oxytocin calculated on the anhydrous and acetic-acid-free basis. Identification includes chromatographic and peptide-specific characterization.
Published comparisons of pharmacopoeial specifications also show that oxytocin API quality is evaluated using related-substance testing and biological activity, with different pharmacopoeias applying different acceptance criteria. For example, the USP 40 comparison reported a biological potency requirement of NLT 400 USP Oxytocin Units/mg, while older Ph. Eur. and IP specifications used different approaches.
Therefore, the specification used on an API CMS page should identify the applicable pharmacopoeial standard rather than incorrectly treating oxytocin like a conventional synthetic small molecule.
HPLC is an important analytical technique for oxytocin. Published pharmacopoeial-method comparisons identify an ODS column of 120 × 4.6 mm, 5 µm for the USP 42 related-substance method, with UV detection at 220 nm. The USP 42 acceptance criterion reported in the literature is total impurities NMT 5.0% of the area of the oxytocin peak.
A typical peptide-analysis approach uses reversed-phase chromatography to separate intact oxytocin from oxidation products, hydrolysis products, deletion sequences and other related substances.
Because oxytocin is a peptide, amino-acid analysis is useful for confirming its composition. The expected residues are:
These analytical characteristics help differentiate correctly structured oxytocin from peptide-related impurities.
Oxytocin is generally described as a white or almost white, hygroscopic powder. The Indian Pharmacopoeia draft proposal describes it in this manner and identifies the pharmaceutical material as a freeze-dried form available as an acetate.
Oxytocin is very soluble in water and can dissolve in dilute solutions of acetic acid and ethanol. Its peptide nature and hygroscopic character mean that appropriate moisture protection and temperature-controlled storage are important.
A regulatory assessment of an oxytocin injection product describes the drug substance as a white or almost white fluffy powder, very soluble in water, and notes that the substance has a Ph. Eur. monograph.
Biological activity is one of the most important quality attributes of oxytocin. The peptide's pharmacological effect depends on the integrity of its cyclic structure and disulfide bond.
For this reason, biological potency may be expressed in international/oxytocin units per milligram rather than simply as a percentage of chemical purity. Historical USP specifications have used biological activity values, and published pharmacopoeial comparisons demonstrate that different compendia have used different potency limits.
Therefore, biological potency should not be replaced by an arbitrary HPLC percentage in a regulatory CMS specification.
Oxytocin API should be stored under controlled conditions appropriate for peptide stability. Published pharmacopoeial comparisons identify 2–8°C as the API storage condition for several major pharmacopoeias, with protection from light in some standards.
The Indian Pharmacopoeia draft specifically describes the material as hygroscopic, making protection from moisture particularly important.
Oxytocin API manufacturing requires specialized peptide synthesis, purification, folding/cyclization and analytical characterization. Production controls should ensure the correct amino-acid sequence, disulfide-bond formation, peptide purity and biological activity.
For pharmaceutical applications, Oxytocin API should be evaluated using appropriate validated analytical methods, including chromatographic purity, identity testing, amino-acid analysis and biological potency testing where required.
Because oxytocin is a peptide API, the anhydrous/acetic-acid-free basis, peptide-related impurities, water content and biological activity must be considered when interpreting assay results.
| Parameter | Specification |
|---|---|
| Appearance | white to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 93.0–102.0% |
| pH (1% Solution) | 3.0 – 6.0 |
| Individual Impurity | NMT 0.5% |
| Water Content | NMT 5.0% |